3 completed, 3 terminated, 1 active not recruiting. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 3, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow dinaciclib: new trials by email Literature Review of dinaciclib trials Research Report on dinaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| Dinaciclib in Treating Patients With Stage IV Melanoma Dinaciclib - Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2009-07-01 | 2026-09-14 |
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma dinaciclib, laboratory biomarker analysis - Refractory Multiple Myeloma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2009-07-01 | 2014-06-18 |
| SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) SCH 727965, Bortezomib, Alemtuzumab - Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 8 | 2009-03-01 | 2015-08-07 |
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) SCH 727965, Gemtuzumab ozogamicin - Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 29 | 2009-01-01 | 2015-02-04 |
| SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) SCH 727965, Capecitabine, Erlotinib - Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck Sharp & Dohme LLC | 97 | 2008-07-01 | 2015-08-05 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Melanoma (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1) · Lymphoma, Mantle-Cell (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
National Cancer Institute (NCI) (4) · Merck Sharp & Dohme LLC (3)
United States (4) · Singapore (1)
Christopher D Lao (1) · Frank Hodi (1) · Kerry Rogers, MD (1) · Shaji Kumar (1)
PMID 23949430, PMID 24388167, PMID 24393852, PMID 25395429, PMID 39342463
N01CM00070 (1), N01CM62205 (1), N01CM62207 (1), P30CA006516 (1), P30CA015083 (1), P30CA016058 (1), P50CA140158 (1), U01CA062490 (1), U01CA076576 (1), U10CA032102 (1), UM1CA186712 (1)